Orchestra BioMed Holdings, Inc. (OBIO) News
Follow Orchestra BioMed Holdings, Inc. (OBIO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
OBIO - Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
OBIO - Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
NEWS | Sep 16, 2026, 12:30 PM UTC
L
Orchestra BioMed Holdings Price Target Raised to $11.00/Share From $10.00 by B. Riley Securities
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 04:20 PM UTC
L
Orchestra BioMed Receives $6.1M Milestone From Vivasure Deal
Orchestra BioMed received $6.1M on Sept. 14, 2026 as the first milestone from Haemonetics’ acquisition of Vivasure, bringing 2026 proceeds to about $11M. The company may receive up to about $10M more via future revenue e
MNA | Sep 15, 2026, 12:34 PM UTC
L
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strate
MNA | Sep 15, 2026, 12:33 PM UTC
L
OBIO - Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
OBIO - Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
MNA | Sep 15, 2026, 12:30 PM UTC
L
BTIG sets Orchestra BioMed price target at $10.00
Benzinga (via TradingView News) reports BTIG announced a $10.00 per-share price target for Orchestra BioMed Holdings.
EQUITY | Sep 10, 2026, 10:06 AM UTC
L
Orchestra BioMed presents slide deck on AVIM, Virtue SAB programs
Orchestra BioMed disclosed a slide presentation outlining AVIM Therapy and Virtue SAB pivotal programs, strategic funding of more than $185 million and 2027 trial and commercialization milestones.
REGULATION | Sep 08, 2026, 01:34 PM UTC
L
Orchestra Biomed announces inducement grants under Nasdaq Rule 5635(c)(4)
Orchestra Biomed Holdings Inc said it has announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 02, 2026, 08:14 PM UTC
L
Orchestra BioMed announces Nasdaq inducement grants under Rule 5635(c)(4)
OBIO said it is announcing inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 02, 2026, 08:05 PM UTC
L
Orchestra BioMed to Participate in H.C. Wainwright conference
Orchestra BioMed (OBIO) will participate in the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Aug 27, 2026, 12:37 PM UTC
L
Orchestra BioMed to participate in Wells Fargo healthcare conference
Orchestra BioMed says it will participate in the Wells Fargo 21st Annual Healthcare Conference.
EQUITY | Aug 20, 2026, 12:30 PM UTC